Latest News
The Fifty-Year Chase: Where Noninvasive Glucose Monitoring Stands in 2026
For nearly half a century, one problem has raised more capital, had more publications, and experienced more failed product launches than almost any other in medical devices: noninvasive glucose monitoring, or measuring blood glucose without breaking the skin. More...
Latest News
Who Notices When a Clinical Model Drifts?
Most clinical prediction tools get one big exam. Someone pulls a retrospective cohort, runs the numbers, shows a committee a curve, and the tool goes live. After that the exam rarely gets repeated, so model drift can go unnoticed. The emergency department keeps...
UK Lab Space in 2026: Record Vacancy, Regional Squeeze
UK lab space demand reached a record in 2026. So did UK lab space vacancy. CoStar data shows national laboratory vacancy hit a record 14.3% in the second quarter of 2026. That is more than double the level of two years earlier. Yet some regional science parks say...
Dostarlimab Rectal Cancer: Will the NHS Offer It Outside Wales?
The NHS has made no UK-wide decision on dostarlimab rectal cancer treatment, as of 20 October 2026. The US Food and Drug Administration (FDA) granted accelerated approval on 19 October 2026. The product is GSK’s Jemperli (dostarlimab). Wales has supported off-label...
When the AI Inside a Medical Device Belongs to Someone Else
Medical device manufacturers have long relied on third-party technology. Generative AI, however, presents new challenges for manufacturers of AI medical devices, who may have little influence over how the external model is developed. The technology may be outside of...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Clinical Trials Roundup | 11 Sept 2026
Novo Nordisk’s semaglutide meets its primary endpoint in children aged six to under 12 in the Phase 3 STEP Young obesity trial, Novartis’s del-desiran misses its primary endpoint in the Phase 3 HARBOR study in myotonic dystrophy type 1, Pharvaris’s deucrictibant XR...
Most Favoured Nation Pricing: What 26 Company Agreements Actually Commit To
Most favoured nation pricing is now the central instrument of United States drug pricing policy. On 31 August 2026, the White House announced agreements with nine further manufacturers. That brought the administration’s stated total to 26 companies, covering 89 per...
Partial Clinical Hold Lands on Opakalim Before SK Deal Closes
The US Food and Drug Administration has imposed a partial clinical hold on Biohaven’s epilepsy candidate opakalim. The hold took effect on 4 September 2026. Biohaven disclosed it in a Form 8-K filed on 10 September 2026. The measure stops new enrolment across the...
The Other Half of Innovation
What does the word "innovation" typically evoke in wound care? For many, it brings to mind a new biomaterial, a novel mechanism, or a breakthrough product supported by promising data and clinical validation. These advancements matter. But they raise a more fundamental...
Rakuten Medical Appoints Former Takeda CEO Christophe Weber to Board
Rakuten Medical Appoints Christophe Weber as Vice Chairman and Ken Takeshita, M.D., as Director to Accelerate US Growth and Oncology Innovation Enhanced Board and leadership team, including the appointment of a new Chief Medical Officer, strengthens governance,...
Why Hormone Health Knowledge Could Improve Female Staff Retention
The life sciences sector is built on evidence, innovation and better health outcomes. So why is women’s hormone health at work still so often treated as a peripheral issue, asks Sarah Davies, Managing Director of Balance@Work? Life sciences organisations spend their...
Tozorakimab COPD Trial Data Reach Below the Eosinophil Gate
AstraZeneca released the full tozorakimab COPD trial results on 8 September 2026. The company presented them as a late breaker at the European Respiratory Society Congress in Barcelona. The slot was the ALERT-2 plenary session. The New England Journal of Medicine...
Section 232 Pharma Tariffs: What Changes on 29 September
On 29 September 2026, Section 232 pharma tariffs reach every company not named in Annex III. The default rate is 100 per cent ad valorem. It applies to patented finished medicines and their associated ingredients. That means active pharmaceutical ingredients and key...
Regenerative Biologics and Biomaterials in Modern Aesthetic Surgery
The Shift Toward Regenerative Surgery When I trained, the reconstructive mindset in plastic surgery was largely mechanical. The goal was to restore form by moving tissue, removing what was damaged, or replacing what was missing, while accepting some degree of scarring...
Coming Off Weight Loss Injections: The Oral Maintenance Option
Orforglipron (Foundayo) is now available in the UK following The Medicines and Healthcare products Regulatory Agency (MHRA) approval on 10 August, making the UK the first European country to license it for weight management and type 2 diabetes. The first oral...
Camizestrant Approval Makes ctDNA Progression a Regulatory Endpoint
The camizestrant approval granted by the US Food and Drug Administration on 4 September 2026 sets an oncology precedent. It is the first US clearance of a cancer therapy triggered by a resistance mutation found in blood. The agency made that claim itself. The trigger...
CBD Vaping: When Product Innovation Outpaces the Science
Early research offers insight, but major gaps remain in understanding long term respiratory effects The rapid rise of CBD vaping products has outpaced the science and regulatory frameworks needed to fully understand their health implications. While early research...
Clinical Trials Roundup | 11 Sept 2026
Novo Nordisk’s semaglutide meets its primary endpoint in children aged six to under 12 in the Phase 3 STEP Young obesity trial, Novartis’s del-desiran misses its primary endpoint in the Phase 3 HARBOR study in myotonic dystrophy type 1, Pharvaris’s deucrictibant XR...
Most Favoured Nation Pricing: What 26 Company Agreements Actually Commit To
Most favoured nation pricing is now the central instrument of United States drug pricing policy. On 31 August 2026, the White House announced agreements with nine further manufacturers. That brought the administration’s stated total to 26 companies, covering 89 per...
Partial Clinical Hold Lands on Opakalim Before SK Deal Closes
The US Food and Drug Administration has imposed a partial clinical hold on Biohaven’s epilepsy candidate opakalim. The hold took effect on 4 September 2026. Biohaven disclosed it in a Form 8-K filed on 10 September 2026. The measure stops new enrolment across the...
The Other Half of Innovation
What does the word "innovation" typically evoke in wound care? For many, it brings to mind a new biomaterial, a novel mechanism, or a breakthrough product supported by promising data and clinical validation. These advancements matter. But they raise a more fundamental...
Rakuten Medical Appoints Former Takeda CEO Christophe Weber to Board
Rakuten Medical Appoints Christophe Weber as Vice Chairman and Ken Takeshita, M.D., as Director to Accelerate US Growth and Oncology Innovation Enhanced Board and leadership team, including the appointment of a new Chief Medical Officer, strengthens governance,...
Why Hormone Health Knowledge Could Improve Female Staff Retention
The life sciences sector is built on evidence, innovation and better health outcomes. So why is women’s hormone health at work still so often treated as a peripheral issue, asks Sarah Davies, Managing Director of Balance@Work? Life sciences organisations spend their...
Tozorakimab COPD Trial Data Reach Below the Eosinophil Gate
AstraZeneca released the full tozorakimab COPD trial results on 8 September 2026. The company presented them as a late breaker at the European Respiratory Society Congress in Barcelona. The slot was the ALERT-2 plenary session. The New England Journal of Medicine...
Section 232 Pharma Tariffs: What Changes on 29 September
On 29 September 2026, Section 232 pharma tariffs reach every company not named in Annex III. The default rate is 100 per cent ad valorem. It applies to patented finished medicines and their associated ingredients. That means active pharmaceutical ingredients and key...
Regenerative Biologics and Biomaterials in Modern Aesthetic Surgery
The Shift Toward Regenerative Surgery When I trained, the reconstructive mindset in plastic surgery was largely mechanical. The goal was to restore form by moving tissue, removing what was damaged, or replacing what was missing, while accepting some degree of scarring...
Coming Off Weight Loss Injections: The Oral Maintenance Option
Orforglipron (Foundayo) is now available in the UK following The Medicines and Healthcare products Regulatory Agency (MHRA) approval on 10 August, making the UK the first European country to license it for weight management and type 2 diabetes. The first oral...
Camizestrant Approval Makes ctDNA Progression a Regulatory Endpoint
The camizestrant approval granted by the US Food and Drug Administration on 4 September 2026 sets an oncology precedent. It is the first US clearance of a cancer therapy triggered by a resistance mutation found in blood. The agency made that claim itself. The trigger...
CBD Vaping: When Product Innovation Outpaces the Science
Early research offers insight, but major gaps remain in understanding long term respiratory effects The rapid rise of CBD vaping products has outpaced the science and regulatory frameworks needed to fully understand their health implications. While early research...
Featured Articles
Further News
Neurodegeneration Pipeline 2026: Genetic Medicine Leads
Last updated 5 November 2026. The FDA accepted uniQure’s Huntington’s gene therapy application for priority review, with a target action date of 1 May 2027. The neurodegeneration pipeline looks very different from the one that opened 2026. Two events in the first week...
The Future of Collagen Hydrogels in Regenerative Medicine
Collagen hydrogels are still the benchmark for regenerative medicine because they provide cells with an environment that feels biologically familiar. However, the next challenge within this field is no longer proving whether or not collagen works, but in capably...
Novo Nordisk Halts Two IL-6 Heart Failure Trials for Futility
Novo Nordisk has stopped two Phase 3 IL-6 heart failure trials on the advice of an independent monitoring committee. The company notified trial investigators on Friday 4 September 2026. Trade press reported the decision on Monday 7 September. Both studies, HERMES and...
After EMBRAZE: The Wider Race to Preserve Muscle During GLP-1 Treatment
When results from the phase 2 EMBRAZE trial were published in Nature Medicine in June, apitegromab’s combination with tirzepatide became the most visible evidence yet that pharmacological muscle preservation during GLP-1 treatment might be achievable.¹ But...
Is RNA Potency the Problem? Creative Biolabs Webinar on saRNA Delivery
The next breakthrough in RNA therapeutics may depend less on making RNA more powerful and more on solving how efficiently it reaches and functions inside target cells. Creative Biolabs will host the upcoming webinar "Engineering saRNA Delivery Systems for...
Weekly News Roundup | 07 September 2026
Life science news 7 September 2026: two US approvals, a UK suspension, a Phase 3 failure and four global deals. PharmaEssentia won FDA approval for Besremi in essential thrombocythemia, a label expansion for the interferon therapy. The MHRA suspended Avacopan Vifor...
Alexander Disease Treatment Approved: What It Means for UK Access
The United States Food and Drug Administration has approved the first Alexander disease treatment. Zanvastro (zilganersen) was cleared on 3 September 2026 for paediatric and adult patients. Ionis Pharmaceuticals developed the antisense oligonucleotide. The decision...
Pelacarsen Trial Miss Leaves Lp(a) Lowering Unproven
Novartis has reported that the pelacarsen trial missed its primary endpoint. The Phase III study, called Lp(a)HORIZON, enrolled 8,323 patients with established cardiovascular disease and elevated lipoprotein(a). The company announced the topline result on 4 September...
Ivonescimab Overall Survival Win Leaves the Key Numbers Undisclosed
Akeso has reported that ivonescimab beat pembrolizumab on overall survival in a Chinese Phase III trial. HARMONi-2 is the fourth Phase III trial of ivonescimab to meet an overall survival endpoint. The ivonescimab overall survival result is the first against...
New Biology, New Opportunities in Women’s Health
Capital is moving into women’s health. But the science may give it even more reason to stay. Across the field, substantial unmet need is converging with rapidly advancing science and enormous areas of unexplored biology. Advances in genetics, molecular biology,...
Clinical Trials Roundup | 4 Sept 2026
Cytokinetics' aficamten meets both primary endpoints in the Phase 3 ACACIA-HCM trial in non-obstructive hypertrophic cardiomyopathy, Takeda and Protagonist's Mimrylo receives FDA approval as the first hepcidin mimetic for polycythaemia vera, Gilead's Bixlenvo is...
The Scale-Up Test
A lab result is only the beginning I have spent close to 20 years developing pharmaceutical, nutraceutical and consumer health products. One lesson has followed me through almost every role: a formula can work beautifully in the laboratory and still become a problem...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.